Pranas Šerpytis

TL;DR: Among patients who had multivessel coronary artery disease and acute myocardial infarction with cardiogenic shock, the 30‐day risk of a composite of death or severe renal failure leading to renal‐replacement therapy was lower among those who initially underwent PCI of the culprit lesion only than amongThose who underwent immediate multivessels PCI.

TL;DR: Among patients with heart failure and a reduced ejection, patients who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo.

TL;DR: Among patients with acute myocardial infarction and cardiogenic shock, the risk of death or renalreplacement therapy at 30 days was lower with culprit‐lesion‐only PCI than with immediate multivessel PCI, and mortality did not differ significantly between the two groups at 1 year of follow‐up.

TL;DR: Omecamtiv mecarbil dosing guided by pharmacokinetics achieved plasma concentrations associated with improved cardiac function and decreased ventricular diameter, and the frequency of adverse clinical events did not differ between groups.

TL;DR: The CULPRIT-SHOCK study is designed to compare culprit lesion only percutaneous coronary intervention (PCI) with possible staged non-culprit lesion revascularization versus immediate multivessel PCI in patients with CS complicating acute myocardial infarction.